Capmatinib, cabozantinib, and tepotinib in combination with EGFR-TKIs have already yielded promising antitumor activity in EGFR-mutated, MET-amplified NSCLC patients [16,18,32]. Here, MET is linked to non-small cell lung carcinoma.